threo-2,3-Hexodiulosonic acid | 3409-57-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: threo-2,3-Hexodiulosonic acid
• 英文别名: (4S,5R)-4,5,6-trihydroxy-2,3-dioxohexanoic acid
• CAS: 3409-57-2
• 化学式: C₆H₈O₇
• 分子量: 192.12
• InChiKey: GJQWCDSAOUMKSE-GBXIJSLDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  脱氢抗坏血酸 生成 threo-2,3-Hexodiulosonic acid
  参考文献：
  名称：

  BAKER, W. L., J. CHEM. TECHNOL. AND BIOTECHNOL., 1984, 34, N 5, 227-236

  摘要：

  DOI：

文献信息

• Combination therapy for metastatic cancer
  申请人：General Oncology, Inc.

  公开号：US11154520B2

  公开（公告）日：2021-10-26

  The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and/or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol.

  本发明涉及有效治疗转移性癌症的方法和成套药物，以及服用能克服对DNA损伤剂的抗药性机制的成套药物，从而使癌细胞对所述DNA损伤剂敏感。这些方法包括服用由美法仑、BCNU、羟钴胺和抗坏血酸组成的一组药物。在一个优选的实施方案中，乙醇也被添加到这套药物中，并通过输注骨髓干细胞来逆转骨髓毒性。这些方法还包括消耗肿瘤中的 GSH 以及选择性地向实体瘤输送药物。这些方法还涉及防止过氧化氢酶功能的丧失，以及防止氧化剂诱导的溶血和/或高铁血红蛋白的形成，受试者使用氧化剂药物或产生过氧化氢的制剂治疗，其中所述方法包括全身给药乙醇。
• COMBINATION FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER IN PATIENTS
  申请人：General Oncology, Inc.

  公开号：EP3386546A1

  公开（公告）日：2018-10-17
• Combination For The Effective Treatment Of Metastatic Cancer In Patients
  申请人：General Oncology, Inc.

  公开号：US20180338935A1

  公开（公告）日：2018-11-29

  The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and/or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol.
• Combination Therapy for Metastatic Cancer
  申请人：General Oncology, Inc.

  公开号：US20220096405A1

  公开（公告）日：2022-03-31

  The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and/or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol.
• [EN] BIOMARKERS OF REDUCED INSULIN ACTION<br/>[FR] MARQUEURS BIOLOGIQUES D'UNE ACTION RÉDUITE DE L'INSULINE
  申请人：MAYO FOUNDATION

  公开号：WO2012058298A1

  公开（公告）日：2012-05-03

  This document provides methods and materials for assessing metabolic disorders related to reduced insulin action (e.g. insulin resistance or insulin deficiency) in a mammal (e.g. human). For example, methods and materials for assessing insulin resistance, risk of developing insulin resistance and monitoring efficacy of insulin resistance treatment are provided.